LYT-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ELEVATE)

PureTech Health

Status and phase: Active, not recruiting; Phase 2

Conditions: Idiopathic Pulmonary Fibrosis

Treatments: Drug: Deupirfenidone; Drug: Placebo; Drug: Pirfenidone

Study type: Interventional

Funder types: Industry

Identifiers

NCT05321420

LYT-100-2022-204

Details and patient eligibility

About

This study a randomized, double-blind, four arm study to evaluate the safety and efficacy of LYT-100 compared to pirfenidone or placebo in adults with Idiopathic Pulmonary Fibrosis.

Full description

This study is a randomized, double-blind, being conducted at centers globally to evaluate the safety and efficacy of LYT-100 compared to pirfenidone or placebo in 240 treatment naïve adult patients with IPF ≥ 40 years in age. Patients will be randomized in a ratio of 1:1:1:1 to receive treatment of LYT-100, pirfenidone, or placebo to be taken daily for up to 183 days (26 week treatment period) with the primary outcome of Rate of decline in Forced Vital Capacity (FVC; in mL) over 26 weeks. Secondary endpoints, including spirometry, inflammatory biomarkers, and patient-reported outcomes will also be evaluated.

After completion of the double-blind period of the study, patients may participate in a long-term extension to evaluate tolerability and long-term safety. Patients receiving LYT-100 in the double-blind period will continue the dose throughout the long-term extension. Patients receiving pirfenidone or placebo in the double-blind period will be re-randomized in a 1:1 ratio to receive LYT-100 550mg or 825mg TID dose throughout the long-term extension.

Enrollment: 240 estimated patients

Sex: All

Ages: 40+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Key Inclusion Criteria:

• Treatment naïve patients or those with <6 months of exposure to nintedanib with physician diagnosed IPF based on ATS/ERS/JRS/ALAT 2018 guidelines
• Idiopathic Pulmonary Fibrosis on HRCT, performed within 12 months of Visit 1 as confirmed by central readers
• DLCO corrected for Hemoglobin (Hb) [visit 1] ≥ 30% and ≤90% of predicted of normal
• FVC ≥ 45% of predicted normal

Key Exclusion Criteria:

• Primary obstructive airway physiology (pre-bronchodilator FEV1/FVC < 0.7 at Visit 1)

• Known explanation for interstitial lung disease, including but not limited to radiation, sarcoidosis, hypersensitivity pneumonitis, bronchiolitis obliterans organizing pneumonia, human immunodeficiency virus (HIV), viral hepatitis, and cancer

• Diagnosis of any connective tissue disease, including but not limited to scleroderma/systemic sclerosis, polymyositis/dermatomyositis, systemic lupus erythematosus, and rheumatoid arthritis

• Major extrapulmonary physiological restriction (e.g., chest wall abnormality, large pleural effusion)

• Cardiovascular diseases, any of the following:

  • Uncontrolled hypertension, within 3 months of Visit 1
  • Myocardial infarction within 6 months of Visit 1
  • Unstable cardiac angina within 6 months of Visit 1

• Prior hospitalization for confirmed COVID-19, acute exacerbation of IPF or any lower respiratory tract infection within 3-months of Visit 1

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

240 participants in 4 patient groups, including a placebo group

Placebo

Placebo Comparator group

Description:

Placebo oral administration

Treatment:

Drug: Placebo

pirfenidone 801 mg TID

Active Comparator group

Description:

pirfenidone 801 mg TID oral administration

Treatment:

Drug: Pirfenidone

LYT-100 550 mg TID

Experimental group

Description:

LYT-100 (Deupirfenidone) 550 mg TID oral administration

Treatment:

Drug: Deupirfenidone

LYT-100 825 mg TID

Experimental group

Description:

LYT-100 (Deupirfenidone) 825 mg TID oral administration

Treatment:

Drug: Deupirfenidone